The Belgian investment company Gimv announced on Tuesday that it had participated in the last funding round of 71 million Swiss francs (74 million dollars) carried out by the biotech ImmunOs Therapeutics.
This series B financing, marked by the arrival of new venture capital funds beyond existing investors such as its Pfizer Ventures, BioMed Partners and Schroder Adveq, should make it possible to launch future clinical trials on IOS-1002, the candidate the most advanced of ImmunOs.
This multifunctional protein blocks specific receptors to initiate anti-tumor responses, an approach that could also be used to develop antibodies to block the activation of molecules specific to autoimmune diseases.
The IOS-1002 program should enter a phase 1 clinical study during the second half of the year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.